Appili Therapeutics to Present as Part of Canada’s Top Three Pitches at Biocom’s Global Life Science Partnering Conference Today
HALIFAX, Nova Scotia, February 24, 2021 – Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the Company or Appili), a biopharmaceutical company developing anti-infective drug candidates, today announced that it will present at the fully virtual Biocom Global conference.
The Company will be discussing the role of favipiravir, the broad spectrum anti-viral therapy approved to treat influenza in Japan, as a potential addition to the treatment toolbox against COVID-19. Appili has recently established a consortium with Dr. Reddy’s Laboratories Ltd., Global Response Aid, and FUJIFILM Toyama Chemical Co., Ltd. to advance the clinical development of favipiravir, including the Phase 3 PRESECO study evaluating favipiravir for the early treatment of mild-to-moderate COVID-19 infections. In addition, the Company will provide information about their investigational anti-fungal compound ATI-2307, which has been designed to address difficult-to-treat fungal infections with high rates of mortality.
Armand Balboni, MD, PhD, Chief Executive Officer (CEO) of Appili Therapeutics will host virtual one-on-one investor meetings throughout the conference and is scheduled to present as follows:
Biocom Global Conference: February 23rd- 25th 2021
Presentation Date: February 24th
Presentation Time: 10:55am PST (1:55 pm EST)
About Biocom Global
The 2021 Keynote Panel at Biocom Global this year, Power of Collaboration: Partnering to Save Patients in a Pandemic, includes a line-up of speakers including Kate Bingham, Chair, UK Vaccine Task Force and Managing Director of SV Health Investors; John Reed, MD, PhD Executive Vice President Global Head of Research & Development, Sanofi; Moncef Slaoui, Partner, Medicxi, the Scientific Head of Operation Warp Speed.
About Appili Therapeutics
Appili Therapeutics is an infectious disease biopharmaceutical company that is purposefully built, portfolio-driven, and people-focused to fulfill its mission of solving life-threatening infections. By systematically identifying urgent infections with unmet needs, Appili’s goal is to strategically develop a pipeline of novel therapies to prevent deaths and improve lives. As part of a global consortium, Appili is sponsoring late-stage clinical trials evaluating the antiviral Avigan® / REEQONUS™(favipiravir) for the worldwide treatment and prevention of COVID-19. The Company is also advancing a diverse range of anti-infectives, including a broad-spectrum antifungal, a vaccine candidate to eliminate a serious biological weapon threat, and two novel antibiotic programs. Led by a proven management team, Appili is at the epicenter of the global fight against infection. For more information, visit .
US/Trade Media Contact:
Sam Brown Inc.
Sam Brown Inc.
T: 613-319-4384 (CAN)
T: 805-242-3080 (U.S.)
Investor Relations Contacts:
Kimberly Stephens, CFO
Laura Kiernan, IRC, CPA
High Touch Investor Relations